Iovance Biotherapeutics Files 8-K for Other Events and Exhibits
Ticker: IOVA · Form: 8-K · Filed: Feb 22, 2024 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Feb 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.000041666, $9.15, $197.1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K filing, corporate-disclosure, regulatory-filing
TL;DR
**IOVANCE BIOTHERAPEUTICS just filed an 8-K for 'Other Events' and 'Financial Statements and Exhibits' on Feb 22, 2024, so keep an eye out for details.**
AI Summary
IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on February 22, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, incorporated in Delaware with IRS number 75-3254381, has a business address at 825 Industrial Road, Suite 400, San Carlos, CA.
Why It Matters
This filing provides public disclosure of significant events or financial information, ensuring transparency for investors and compliance with SEC regulations.
Risk Assessment
Risk Level: low — The filing itself is a standard disclosure and does not inherently indicate a high risk, though the underlying 'Other Events' could be significant.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- Delaware (company) — State of Incorporation
- February 22, 2024 (date) — Date of Report
- 75-3254381 (dollar_amount) — I.R.S. Employer Identification No.
- 825 Industrial Road , Suite 400 San Carlos (company) — Business Address
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is IOVANCE BIOTHERAPEUTICS, INC.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was February 22, 2024.
In which state is IOVANCE BIOTHERAPEUTICS, INC. incorporated?
IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.
What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?
The Commission File Number for IOVANCE BIOTHERAPEUTICS, INC. is 001-36860.
What items were reported in this 8-K filing?
This 8-K filing reported 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2024-02-22 16:53:39
Key Financial Figures
- $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
- $9.15 — closed offering at an offering price of $9.15 per share before underwriting discounts
- $197.1 million — fering are expected to be approximately $197.1 million after deducting the underwriting discou
Filing Documents
- tm246821d3_8k.htm (8-K) — 26KB
- tm246821d3_ex5-1.htm (EX-5.1) — 8KB
- tm246821d3_ex5-1img01.jpg (GRAPHIC) — 7KB
- 0001104659-24-026578.txt ( ) — 215KB
- iova-20240222.xsd (EX-101.SCH) — 3KB
- iova-20240222_lab.xml (EX-101.LAB) — 33KB
- iova-20240222_pre.xml (EX-101.PRE) — 22KB
- tm246821d3_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On February 22, 2024, Iovance Biotherapeutics, Inc. (the "Company") closed the sale of an aggregate of 23,014,000 shares of its common stock, $0.000041666 par value per share (the "Shares"), in its previously disclosed offering at an offering price of $9.15 per share before underwriting discounts and commissions (the "Offering"). The total net proceeds to the Company from the Offering are expected to be approximately $197.1 million after deducting the underwriting discounts and commissions and estimated Offering expenses payable by the Company. A copy of the opinion of DLA Piper LLP (US) relating to the validity of the Shares issued in the Offering is filed herewith as Exhibit 5.1.
01. Financial
Item 9.01. Financial (d) Exhibits. Exhibit Number Description 5.1 Opinion of DLA Piper LLP (US) 104 Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iovance Biotherapeutics, Inc. Dated: February 22, 2024 By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D. Title: Interim CEO and General Counsel